Melanotan II (MT-II): A Non-Selective Melanocortin Agonist — Research, Safety, and Regulatory Status

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to Melanotan II (MT-II). Melanotan II is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

The internet describes it as a shortcut to a tan without sun exposure. Bodybuilding forums and gray-market vendors have sold vials of it for decades. What those sources rarely describe is the mechanism behind it, or what the published medical literature says about the moles that can darken and grow within 24 hours of a single injection, the melanoma cases that followed, or the surgical emergencies requiring penile decompression.

This article covers what Melanotan II is, how it acts on melanocortin receptors across multiple organ systems, what the clinical evidence documents in terms of safety, and why both the FDA and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have issued public warnings about it.

Key Takeaways

• Regulatory Status: As of April 2026, Melanotan II is not FDA-approved for any indication and has never received regulatory approval in any jurisdiction. The MHRA issued a public warning in 2009. The FDA has issued warning letters to domestic distributors. It is not classified as a bulk drug substance eligible for compounding.
• Research Stage: Limited early-phase human data from small pilot studies conducted in the 1990s and 2000s; no completed Phase III efficacy or safety trials. Safety signals from case reports published through 2025.
• Availability: Not legally marketed for human use. Superpower does not offer this substance. Products sold online as "research use only" are unregulated.
• What it is: A synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates all four peripheral melanocortin receptors non-selectively.
• What the evidence actually shows: Small human studies confirmed skin tanning and erection induction alongside dose-limiting nausea and flushing; multiple published case reports associate use with melanoma, dysplastic nevus eruption, priapism requiring surgery, rhabdomyolysis, renal infarction, and posterior reversible encephalopathy syndrome (PRES). As of April 2026, no completed human safety or efficacy trial has been published.
• Compound reference data: PubChem CID 2656580

Where Melanotan II Comes From and How It Works

Origin and discovery

Melanotan II was developed at the University of Arizona in the late 1980s and early 1990s as a candidate chemopreventive agent: the hypothesis was that controlled induction of melanogenesis might reduce UV-induced DNA damage and skin cancer risk. The compound is a synthetic, cyclized analog of [Nle4,D-Phe7]-α-MSH, a superpotent linear melanotropin first characterized in a 1980 paper by Sawyer, Sanfilippo, Hruby, and Hadley in the Proceedings of the National Academy of Sciences, reported to be approximately 26 times more potent than native α-MSH in the mouse melanoma adenylate cyclase assay and resistant to enzymatic degradation by serum proteases. MT-II introduced a lactam bridge that further stabilized the peptide backbone against proteolysis, increasing both potency and receptor residence time. It does not occur naturally in the body; it is a laboratory-synthesized research compound.

Proposed mechanism: non-selective melanocortin receptor agonism

The melanocortin system comprises five G-protein-coupled receptors (MC1R through MC5R), each with distinct tissue expression and physiological roles. Native α-MSH shows preferential activity at MC1R, which is located on melanocytes and mediates eumelanin synthesis. Melanotan II is a non-selective agonist: it binds and activates MC1R, MC3R, MC4R, and MC5R with broadly comparable affinity. That non-selectivity is clinically significant because the effects observed in the small human studies conducted in the 1990s were not limited to pigmentation. MC4R activation in the hypothalamus and spinal cord drives erection and sexual arousal. MC3R and MC5R activation produces a range of autonomic effects including suppression of appetite, altered cardiovascular tone, and changes in exocrine secretion. The erection effect was not anticipated during the drug's original development as a tanning agent — it emerged as an adverse finding in the first human pilot trial and subsequently redirected research toward sexual dysfunction as a secondary indication. The mechanism underlying pigmentation, which is the reason most users self-administer the compound, is activation of MC1R on melanocytes, triggering the cAMP-PKA signaling cascade that upregulates tyrosinase and drives production of eumelanin (brown-black pigment) rather than phaeomelanin (yellow-red pigment).

What the early human research showed

The foundational human study was a pilot trial published by Dorr and colleagues in 1996 in Life Sciences, in which three healthy male volunteers received subcutaneous MT-II at escalating doses. The study confirmed dose-dependent skin tanning but also documented dose-limiting nausea, flushing, and spontaneous penile erections as the primary adverse effects. A subsequent preformulation and stability study by Lan, Ugwu, and colleagues, published in the Journal of Pharmaceutical Sciences in 1994, characterized the physicochemical properties of melanotan-II as a candidate skin-cancer chemopreventive peptide. Separate human pharmacokinetic work by Ugwu, Blanchard, and colleagues, published in Biopharmaceutics and Drug Disposition in 1997, characterized the linear analog melanotan-I, demonstrating complete subcutaneous bioavailability and pigmentation lasting more than three weeks after a single dose — a useful contrast to the cyclic, non-selective MT-II. These studies were conducted in the context of cancer prevention research, not as a basis for consumer self-administration. No Phase III trials were ever conducted. The compound was never submitted for FDA approval, and its subsequent circulation as a gray-market injectable product was not the outcome its developers intended.

The Sexual Function Lineage: MT-II and Bremelanotide

The unexpected erectile response observed in the 1996 pilot trial led to a formal research program at the University of Arizona. Wessells and colleagues published a double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction in the Journal of Urology in 1998, reporting that MT-II produced clinically apparent erections in 8 of 10 participants versus 0 of 10 on placebo, with mean tip rigidity exceeding 80% and erections lasting a mean of 38 minutes. A follow-on double-blind, placebo-controlled crossover study published in Urology in 2000 enrolled 10 men with organic erectile dysfunction — including those with diabetes, hypertension, and post-prostatectomy status — each of whom received two active (MT-II 0.025 mg/kg subcutaneous) and two placebo injections; subjectively reported erections occurred after 12 of 19 MT-II injections versus 1 of 21 placebo injections, mean rigidity scores reached 6.9/10 among responders, and duration of tip rigidity >80% averaged 45.3 vs 1.9 minutes (p = 0.047), with 4 of 19 active-drug injections producing severe nausea — a small, short-observation cohort that provided proof-of-concept rather than confirmatory efficacy data. A review synthesizing these data, published in the International Journal of Impotence Research in 2000, established that MT-II acts centrally through hypothalamic MC4R signaling — a mechanism mechanistically distinct from phosphodiesterase-5 inhibitors, which act peripherally via the nitric oxide and cyclic GMP pathway in corporal tissue.

This research ultimately contributed to the development of bremelanotide (PT-141), an N-acetylated cyclic analog of MT-II. Bremelanotide completed the full Phase III clinical trial program and received FDA approval in June 2019 as Vyleesi, indicated for hypoactive sexual desire disorder in premenopausal women. The pivotal RECONNECT Phase III program, reported by Kingsberg and colleagues in Obstetrics and Gynecology in 2019, comprised two identical 24-week double-blind placebo-controlled trials (Studies 301 and 302) enrolling a combined 1,267 premenopausal women with HSDD; bremelanotide 1.75 mg administered subcutaneously as needed produced integrated improvements of +0.35 on the Female Sexual Function Index Desire domain (p < 0.001) and −0.33 on Female Sexual Distress Scale item 13 (p < 0.001) versus placebo, with nausea, flushing, and headache each reported in ≥10% of bremelanotide recipients — the only completed regulatory trial data in this mechanistic class. This comparison is for scientific context only: bremelanotide and Melanotan II have fundamentally different regulatory statuses, evidence bases, and safety profiles. Melanotan II has never undergone the regulatory review process that bremelanotide completed, and the two compounds should not be conflated.

Melanotan II vs. Melanotan I (Afamelanotide): Key Differences

The two compounds are structurally related but clinically distinct. Melanotan I is the linear (non-cyclized) analog of [Nle4,D-Phe7]-α-MSH, now known as afamelanotide. Unlike MT-II, afamelanotide has high selectivity for MC1R and does not significantly activate MC4R at therapeutic doses, which means it produces pigmentation without the erection, nausea, and autonomic effects that characterize MT-II. Afamelanotide completed a full regulated clinical development program: a 2021 focused review by Wensink, Wagenmakers, and colleagues in Expert Review of Clinical Pharmacology summarizes the Phase III RCT evidence base (studies CUV029, CUV030, and CUV039) that supported FDA approval of afamelanotide as Scenesse in October 2019 for phototoxic reactions in adults with erythropoietic protoporphyria. A 2016 drug review by Kim and Garnock-Jones in the American Journal of Clinical Dermatology also covers the afamelanotide evidence base and confirms the drug's narrow approved indication. As of April 2026, afamelanotide is the only MC1R-targeted melanocortin agonist with FDA approval for any indication. Melanotan II has no approved indication anywhere in the world. The existence of an approved, selective MC1R agonist developed through rigorous clinical trials makes the continued gray-market use of the non-selective, unapproved MT-II particularly difficult to justify on grounds of mechanism alone.

Safety: The Published Case Evidence

Nevi changes and melanoma risk

The most clinically consequential safety signals associated with MT-II involve melanocytes: the same cells the compound is intended to stimulate. Multiple published case reports document new nevus formation, rapid darkening and growth of existing nevi, dysplastic nevus eruption, and melanoma following MT-II use.

Schulze, Erdmann, and colleagues reported in the European Journal of Dermatology in 2014 that a single mono-dose subcutaneous MT-II injection produced eruptive naevi and darkening of pre-existing naevi within 24 hours — establishing that visible melanocytic changes can occur after one exposure. Cardones and Grichnik published a case report in the Archives of Dermatology in 2009 documenting a 40-year-old man with a prior melanoma and dysplastic nevus syndrome who self-administered synthetic α-MSH and developed eruptive atypical nevi plus growth of pre-existing nevi, which lightened and regressed after discontinuation — providing mechanistic evidence that synthetic melanocortin agonists can drive proliferation of neoplastic melanocytes in predisposed individuals. Sivyer and Rosendahl reported in Dermatology Practical and Conceptual in 2012 a 16-year-old girl with familial atypical multiple mole melanoma syndrome who developed dysplastic nevus changes after two months of daily MT-II combined with sunbed use, illustrating the risk in individuals with genetic melanoma predisposition.

On melanoma specifically: Ong and colleagues published a case report in the Australasian Journal of Dermatology in 2012 documenting melanoma in situ arising in a nevus that darkened and enlarged during MT-II self-injection. Hjuler and Lorentzen reported in Dermatology in 2014 a case of cutaneous melanoma on the gluteal region in a 20-year-old Fitzpatrick-II woman following MT-II use combined with tanning-bed exposure. A case series published by Paurobally and colleagues in the British Journal of Dermatology in 2011 documented multiple cases of dysplastic nevus eruption and malignant melanoma associated with MT-II use, concluding that "the harmlessness of melanotan should not be promoted" until its effects on melanocyte proliferation and carcinogenesis have been adequately characterized. A 2025 case report by Yassin Alsabbagh, Bhujel, and colleagues in the International Journal of Oral and Maxillofacial Surgery extends the melanoma signal to mucosal sites, describing a 22-year-old otherwise healthy woman who developed an anterior maxillary mucosal malignant melanoma after using MT-II nasal spray for tanning — indicating that the oncogenic risk may not be confined to injection routes or cutaneous sites.

A comprehensive 2017 review by Habbema and colleagues in the International Journal of Dermatology catalogued the full spectrum of reported MT-II harms — melanoma, nevus change, gastrointestinal, cardiovascular, and central nervous system events — and drew an explicit distinction between afamelanotide's regulated clinical development and MT-II's black-market status, concluding that the two compounds should not be treated as equivalent. A 2022 Dutch-language clinical review by Eijmael, Janmaat, and colleagues in Nederlands Tijdschrift voor Geneeskunde documented the tanning-related risks of melanotan ("Barbie drug") products in the European context, including pigmentation changes and dysplastic naevi.

Priapism

Because MT-II activates MC4R-driven erection pathways non-selectively, prolonged and pathological erection is a documented risk. Devlin and colleagues published an early case report in Clinical Toxicology in 2013 documenting MT-II overdose associated with priapism, representing the first formal priapism signal in the literature. Dreyer and colleagues reported in BMJ Case Reports in 2019 a case of low-flow ischemic priapism following abdominal subcutaneous MT-II injection, managed with cavernosal aspiration and intracavernosal phenylephrine, with the patient having not recovered erectile function at four-week follow-up. Mallory and colleagues published a case report in Sexual Medicine in 2021 documenting acute ischemic priapism after MT-II injection that required penoscrotal decompression surgery after failed cavernosal aspiration and phenylephrine irrigation. These reports collectively demonstrate that the MC4R-mediated erectogenic effect that made MT-II interesting to researchers can progress to an irreversible surgical emergency in users who self-inject gray-market product.

Rhabdomyolysis and cardiovascular toxicity

Nelson and colleagues published an emergency-department case report in Clinical Toxicology in 2012 documenting a 39-year-old man who injected six milligrams of subcutaneous MT-II — six times a commonly cited starting dose — and developed systemic sympathomimetic toxicity with tachycardia, mydriasis, diffuse muscle tremors, and rhabdomyolysis. This case illustrates the consequence of dose variability in gray-market products: a vial labeled 10 mg that contains 8 mg, divided into doses using a syringe calibrated for insulin, produces dosing that is neither predictable nor safe. An independent laboratory analysis by Breindahl and colleagues, published in Drug Testing and Analysis in 2015, analyzed MT-II vials purchased from three online shops — each labeled as containing 10 mg — and found that actual peptide content ranged from 4.32 to 8.84 mg, with every vial below the claimed dose; vials from two shops contained unknown impurities at 4.1–5.9% by mass, while vials from the third were below the limit of quantification, providing quantitative evidence that gray-market MT-II is systematically underdosed and variably contaminated. A parallel 2018 review by Callaghan in Dermatology Online Journal mapped the underground melanotan supply chain, user sourcing practices, and purity patterns, adding further context for the regulatory and safety picture.

Renal and central nervous system events

Peters and colleagues reported the first published case of MT-II-associated renal infarction in CEN Case Reports in 2020, proposing both thrombotic and direct nephrotoxic mechanisms. Kaski and colleagues published a case report in Annals of Internal Medicine in 2013 linking MT-II use to posterior reversible encephalopathy syndrome (PRES), a condition characterized by seizures, visual disturbance, and bilateral posterior white-matter abnormalities on MRI — extending the documented safety picture to the central nervous system and its vascular architecture.

Regulatory and Legal Status

FDA status

As of April 2026, Melanotan II has no FDA approval for any indication and has never been submitted for review. It is not classified as a Category 1 bulk drug substance eligible for compounding under Section 503A. The FDA has issued warning letters to domestic distributors of MT-II. It is not legally marketed for human use in the United States in any form or formulation.

MHRA warning (United Kingdom)

The UK Medicines and Healthcare products Regulatory Agency issued a public warning about melanotan products in 2009, discussed in a 2009 BMJ clinical commentary by Langan, Ramlogan, and colleagues that specifically noted the link between MT-II use and mole changes. The MHRA classified MT-II as an unlicensed medicine and stated that its safety had not been established. The compound remains unlicensed in the United Kingdom as of April 2026.

What this means practically

Products labeled as Melanotan II or MT-II sold through online vendors and gray-market sources are not regulated. They are not manufactured under pharmaceutical GMP standards, are not tested for purity or potency by any regulatory body, and have no established dosing guidance validated in human safety trials. The Breindahl 2015 analytical study found that labeled doses were inaccurate in every sample tested. Users have no reliable way to know what dose they are administering, whether the vial contains the compound it claims to contain, or what impurities are present. There is no legal pathway to obtain pharmaceutical-grade Melanotan II for human use in the United States, the United Kingdom, or any jurisdiction where the compound has been subject to regulatory scrutiny.

Who Faces Elevated Theoretical Risk

Based on the compound's documented mechanism and the published case literature, the following groups face elevated risk from MT-II exposure. This is not an exhaustive clinical list.

• Individuals with a personal or family history of melanoma: MC1R activation stimulates melanocyte proliferation. The Cardones and Grichnik (2009) case report demonstrates that even short-term synthetic α-MSH exposure can drive neoplastic melanocyte proliferation in individuals with melanoma history or dysplastic nevus syndrome.
• Individuals with multiple atypical or dysplastic nevi: Published case reports document rapid darkening, enlargement, and malignant transformation of pre-existing nevi, including within 24 hours of a single injection.
• Individuals with familial atypical multiple mole melanoma (FAMMM) syndrome: The Sivyer and Rosendahl (2012) case involving a 16-year-old with FAMMM syndrome illustrates the catastrophic mismatch between genetic melanoma predisposition and MC1R stimulation.
• Men with any predisposition to priapism or vascular thrombosis: MC4R activation can produce pathological erection. Published cases document ischemic priapism progressing to surgical emergency and permanent erectile dysfunction.
• Individuals with cardiovascular disease or elevated blood pressure: Autonomic effects mediated by MC3R and MC5R include vasopressor activity. The Nelson (2012) rhabdomyolysis case included tachycardia and mydriasis consistent with sympathomimetic toxicity.
• Individuals with pre-existing renal or neurological conditions: Case reports document renal infarction and PRES in previously healthy users; baseline vulnerability would amplify these risks.
• Competitive athletes: As of the 2026 WADA Prohibited List, non-approved peptide hormones and their analogs are prohibited under Section S2. MT-II's status as a non-approved substance with hormonal activity makes it subject to this prohibition.
• Minors: The Sivyer and Rosendahl case involved a 16-year-old. Gray-market access creates real exposure in this population.

Which Biomarkers Are Relevant if You Are Exploring Melanocortin Science?

If someone has been exposed to MT-II or is researching the melanocortin system, understanding their baseline biology provides objective context that no amount of internet research can substitute.

• High-sensitivity CRP (hs-CRP): A sensitive marker of systemic inflammation. Relevant as a baseline measure of inflammatory status; elevated values warrant clinical context before introducing any investigational compound.
• eGFR (estimated glomerular filtration rate): Measures kidney filtration function. Given published case reports of MT-II-associated renal infarction, renal function baseline is clinically meaningful for any individual who has used or is considering use.
• GGT and ALT: Liver enzyme markers that establish hepatic function baseline. Relevant to the metabolism and clearance of investigational peptides and to assessing general safety context.
• Hematocrit and hemoglobin: Components of the complete blood count that reflect erythrocyte mass and oxygenation capacity. Rhabdomyolysis (documented in the Nelson 2012 case) produces secondary effects on renal handling of myoglobin, and a CBC baseline provides the context to interpret post-exposure changes.
• Creatinine (via the creatinine test): Measures kidney waste clearance. A baseline creatinine, interpreted alongside eGFR, provides the reference point needed to identify acute renal injury.
• White blood cells (WBC): A general immune activity marker. Infectious contamination from non-sterile gray-market injectables can produce an acute inflammatory response; baseline WBC provides context for evaluating post-injection symptoms.
• Biomarkers relevant to cutaneous melanoma surveillance: A practical guide to melanoma biomarkers provides clinical context for individuals who have been exposed to compounds with documented melanocyte-stimulating activity and who want to understand what objective markers are clinically relevant.

When to Take This Seriously

If you have used Melanotan II and have noticed new moles, changes in existing moles (darker color, irregular borders, rapid growth), or skin changes in any location including mucosal sites, see a dermatologist. This is not precautionary: the published case literature documents melanoma arising in individuals with no prior melanoma history following MT-II use. Pigment changes that develop or accelerate during or after use warrant clinical evaluation regardless of the person's baseline skin type or perceived UV exposure history. The same applies to urological symptoms: prolonged erection following MT-II injection requires emergency medical evaluation; ischemic priapism becomes an irreversible condition within hours.

More broadly, the melanocortin system is not well understood at the level of individual variation. MC1R genotype modulates the pigmentation response, as a 2006 study by Fitzgerald, Fryer, and colleagues in Peptides established — documenting heterogeneous melanin-synthesis responses to [Nle4, D-Phe7]-α-MSH in humans carrying MC1R variant alleles. Who responds to MT-II with tumor-promoting melanocyte proliferation versus unremarkable tanning is not predictable from any currently available consumer test. That uncertainty, combined with the absence of any approved safety data, is the biological argument for leaving gray-market MC receptor agonism alone. That commitment to understanding biology before making decisions about it is what drives Superpower's approach to preventive health: objective biomarker data and clinical context come before every health decision, especially those involving compounds with limited human evidence and documented serious risks.

IMPORTANT SAFETY INFORMATION

Melanotan II (MT-II) is not FDA-approved for any indication and has never received regulatory approval in any jurisdiction. As of April 2026, it is not eligible for pharmaceutical compounding under Section 503A or 503B. Superpower Health does not prescribe, sell, compound, or facilitate access to Melanotan II. This article is provided solely for educational and informational purposes.

Documented serious risks in the published case literature include: cutaneous melanoma (multiple case reports), dysplastic nevus eruption and rapid nevus darkening (including within 24 hours of single-dose injection), oral mucosal malignant melanoma (case report, 2025), ischemic priapism requiring surgical decompression and associated with permanent erectile dysfunction (multiple case reports), rhabdomyolysis and sympathomimetic toxicity (emergency case report), renal infarction (case report), and posterior reversible encephalopathy syndrome (PRES) with seizures and white-matter abnormalities on MRI (case report).

Gray-market products labeled as Melanotan II are not manufactured under pharmaceutical standards. Independent laboratory analysis has confirmed that peptide content in online-sold vials ranges from 4.32 to 8.84 mg in vials labeled as 10 mg, with measurable unknown impurities. Dosing cannot be reliably controlled.

Populations facing elevated theoretical risk include individuals with personal or family history of melanoma, dysplastic nevus syndrome, familial atypical multiple mole melanoma syndrome, active cardiovascular or renal disease, any predisposition to priapism, and minors.

As of the 2026 WADA Prohibited List, non-approved peptide hormones and their analogs are prohibited under Section S2. Competitive athletes should consider MT-II prohibited.

If you have used Melanotan II and have noticed pigment changes, seek dermatological evaluation. If you experience a prolonged erection following MT-II injection, seek emergency medical care immediately.

Additional Questions

What is the difference between Melanotan II and PT-141 (bremelanotide)?

PT-141 (bremelanotide, brand name Vyleesi) is an N-acetylated cyclic analog of MT-II that was specifically developed from MT-II's erection-inducing effect and taken through the full FDA approval process. Bremelanotide received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women based on the pivotal RECONNECT Phase III trials. MT-II is the unapproved precursor compound from which bremelanotide's development lineage originates. They are different molecules with different regulatory statuses and are not interchangeable.

Are peptides legal again in 2026 following the FDA reclassification?

The February 2026 FDA policy developments primarily concerned the compounding status of certain bulk drug substances. Melanotan II was not affected: it was not eligible for compounding before those developments and remains ineligible after them. The reclassification that expanded access to some peptides in compounding pharmacies does not apply to MT-II, which has never been on any list of approved bulk drug substances and has been the subject of FDA warning letters targeting its distribution.

What mole changes should concern someone who has used Melanotan II?

Any new mole, any darkening or enlargement of an existing mole, irregular borders, color heterogeneity, or any mole that has changed in size or shape during or after MT-II use warrants evaluation by a dermatologist. The Schulze 2014 case report documents eruptive naevi and darkening within 24 hours of a single injection; the Ong 2012 and Hjuler 2014 case reports document melanoma following use. There is no safe interval to wait before seeking evaluation of pigment changes in this context.